Abstract

Oxaliplatin is a platinum derivative chemotherapeutic drug widely used against cancers, but even a single treatment can induce a severe allodynia that requires treatment interruption and dose diminution. The rhizome of Zingiber officinale roscoe (Z. officinale, ginger), has been widely used in traditional medicine to treat various diseases causing pain; however, its effect against oxaliplatin-induced neuropathic pain has never been assessed. In mice, a single oxaliplatin (6 mg/kg, i.p.) treatment induced significant cold and mechanical allodynia. Cold and mechanical allodynia were assessed by acetone drop and von Frey filament tests, respectively. Water extracts of Z. officinale (100, 300, and 500 mg/kg, p.o.) significantly attenuated both cold and mechanical allodynia induced by oxaliplatin. Intrathecal pre-treatment with the antagonist 5-HT1A (NAN-190, i.t., 1 μg), but not with the antagonist 5-HT2A (ketanserin, i.t., 1 μg), significantly blocked the analgesic effect of Z. officinale against both cold and mechanical allodynia. However, 5-HT3 antagonist (MDL-72222, i.t., 15 μg) administration only blocked the anti-allodynic effect of Z. officinale against cold allodynia. Real-time PCR analysis demonstrated that Z. officinale significantly increased the mRNA expression of the spinal 5-HT1A receptor that was downregulated after oxaliplatin injection. These results suggest that Z. officinale may be a viable treatment option for oxaliplatin-induced neuropathic pain.

Highlights

  • Oxaliplatin is a widely used chemotherapeutic agent and was the first diaminocyclohexane platinum-based anti-cancer agent to be approved for the treatment of colorectal cancer [1]

  • These results are in accordance with our previous study showing that a single oxaliplatin treatment induced cold and mechanical allodynia 3 to 7 days after injection [8]

  • Cold allodynia was measured by using the acetone drop test, and mechanical allodynia was assessed by using the von

Read more

Summary

Introduction

Oxaliplatin is a widely used chemotherapeutic agent and was the first diaminocyclohexane platinum-based anti-cancer agent to be approved for the treatment of colorectal cancer [1]. It has a better safety profile than cisplatin or carboplatin, which are other platinum-based drugs, as it bears no hepatoxicity or nephrotoxicity [2]. The use of oxaliplatin in cancer patients is limited due to the severe acute neuropathic pain induced even after a single injection in up to 80% of treated patients [3]. An optimal drug has yet to be found, and the development of alternative strategies is continuously needed

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call